The plasma-based qPCR or dPCR assays typically used in the above mentioned reports were mainly directed at ctDNA detection of oncogenic mutations localized at distinct hotspots such as the relatively small exons 18–21 of EGFR, exon 2 of KRAS or exon 15 of BRAF. For longitudinal MRD monitoring this presents a significant limitation, since a large portion of the somatic DNA point mutations in NSCLC are in tumor suppressors, with absence of such hotspots. This evidence concerns the gene BRAF and non-small cell lung carcinoma.